Back to discover
Disease
Lymphopenia
Late-stage therapeutic developmentEmerging research
4
Publications
10
Clinical trials
5
Related conditions
7
Associated genes
2020
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis.
Research2020-08-27European journal of clinical investigation
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
Research2020-07-01Allergy
Research2020-03-29Journal of medical virology
Research2010-06-01Journal of clinical oncology : official journal of the American Society of Clinical Oncology
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 2 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
Results expected Q4 20262026-07-24
Upcoming trial readoutImportant
Results expected Q1 20272026-08-27
Clinical MilestonesViewHide
Results expected
- 2026-08-27A Phase 1 Evaluation of the Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)Results expected Q1 2027
- 2026-07-24An Open-Label, Single-Arm, Phase 1/2 Dose-Escalation Trial of Long-Acting Recombinant Human IL-7 (NT-I7, Efineptakin-Alpha) for Idiopathic CD4 LymphopeniaResults expected Q4 2026
Recently completed
Other updates
- 2029-12-31Phase 3 Randomized, Blinded, Placebo-Controlled Study Evaluating Nogapendekin Alfa Inbakicept and iNKT Cells In Critically Ill Adults With Severe Community-Acquired Pneumonia With or Without Sepsis/Acute Respiratory Distress SyndromeWithdrawn
- 2027-01-15Phase 2 Study Evaluating Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia With or Without Sepsis/Acute Respiratory Distress Syndrome.Withdrawn
Activity timeline5
- 2029-12-31ClinicalPhase 3 Randomized, Blinded, Placebo-Controlled Study Evaluating Nogapendekin Alfa Inbakicept and iNKT Cells In Critically Ill Adults With Severe Community-Acquired Pneumonia With or Without Sepsis/Acute Respiratory Distress SyndromeWithdrawn
- 2027-01-15ClinicalPhase 2 Study Evaluating Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia With or Without Sepsis/Acute Respiratory Distress Syndrome.Withdrawn
- 2026-08-27ClinicalA Phase 1 Evaluation of the Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)Results expected Q1 2027
- 2026-07-31ClinicalEvaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors: A Randomized Withdrawal TrialPrimary completion
- 2026-07-24ClinicalAn Open-Label, Single-Arm, Phase 1/2 Dose-Escalation Trial of Long-Acting Recombinant Human IL-7 (NT-I7, Efineptakin-Alpha) for Idiopathic CD4 LymphopeniaResults expected Q4 2026
Clinical trials
The current development programme across all trial phases.
Clinical programme
10
3
1
3
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20102020
Most influential
Recent publications
Major themes2
- Immunity, Innate1
- Pandemics1
Leading journals4
- Allergy1
- European journal of clinical investigation1
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
- Journal of medical virology1
Leading researchers8
- Ahmadi N1
- Aimo A1
- Akdis CA1
- Akdis M1
- Anders R1
- Azkur AK1
- Azkur D1
- Brahmer JR1
Affiliations (unnormalised)6
- Christine Kühne-Center for Allergy Research and Education1
- Department of Clinical Therapeutics1
- Humanitas Clinical and Research Center - IRCCS1
- Institute for Liver and Digestive Health1
- Institute of Life Sciences1
- IRCCS Policlinico San Donato1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Reduction in the number of lymphocytes.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.